Home/Filings/4/0000899243-22-003924
4//SEC Filing

GRAINGER DAVID J 4

Accession 0000899243-22-003924

CIK 0001847903other

Filed

Jan 31, 7:00 PM ET

Accepted

Feb 1, 8:15 PM ET

Size

6.2 KB

Accession

0000899243-22-003924

Insider Transaction Report

Form 4
Period: 2022-01-28
GRAINGER DAVID J
Chief Innovation Officer
Transactions
  • Purchase

    Ordinary Shares

    2022-01-28$9.05/sh+27,500$248,75427,500 total(indirect: See footnote)
Holdings
  • Ordinary Shares

    813,756
Footnotes (2)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

Issuer

Centessa Pharmaceuticals plc

CIK 0001847903

Entity typeother

Related Parties

1
  • filerCIK 0001887115

Filing Metadata

Form type
4
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 8:15 PM ET
Size
6.2 KB